LY3849891 / Eli Lilly, Novo Nordisk - LARVOL DELTA

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (clinicaltrials.gov) - P1 | N=176 | Active, not recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Oct 2026 ➔ May 2026 | Trial primary completion date: Oct 2026 ➔ May 2026 | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Trial primary completion date • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • PNPLA3

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - P1 | N=176 | Recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Dec 2025 ➔ Sep 2026 | Trial primary completion date: Dec 2025 ➔ Sep 2026

Trial completion date • Trial primary completion date • Hepatology • Metabolic Dysfunction-Associated Steatotic Liver Disease • PNPLA3

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - P1 | N=176 | Recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Nov 2024 ➔ Dec 2025 | Trial primary completion date: Nov 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Hepatology • Metabolic Dysfunction-Associated Steatotic Liver Disease • PNPLA3

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - P1 | N=176 | Recruiting | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Recruiting

Enrollment open • Hepatology • Non-alcoholic Fatty Liver Disease • PNPLA3

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - P1 | N=176 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatology • Non-alcoholic Fatty Liver Disease • PNPLA3

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - P1 | N=176 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatology • Non-alcoholic Fatty Liver Disease

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - P1 | N=176 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Hepatology • Non-alcoholic Fatty Liver Disease